Details for New Drug Application (NDA): 076516
✉ Email this page to a colleague
NDA 076516 describes CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, which is a drug marketed by Actavis Mid Atlantic, Fougera Pharms, Glenmark Speclt, and Taro, and is included in six NDAs. It is available from sixteen suppliers. Additional details are available on the CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE profile page.
The generic ingredient in CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE is betamethasone dipropionate; clotrimazole. There are sixty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; clotrimazole profile page.
The generic ingredient in CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE is betamethasone dipropionate; clotrimazole. There are sixty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; clotrimazole profile page.
Summary for 076516
| Tradename: | CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE |
| Applicant: | Fougera Pharms |
| Ingredient: | betamethasone dipropionate; clotrimazole |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | LOTION;TOPICAL | Strength | EQ 0.05% BASE;1% | ||||
| Approval Date: | Jun 16, 2005 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
